Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Early dual antiplatelet therapy shows superior efficacy in reducing stroke recurrence compared with aspirin monotherapy.

President Trump told the Wall Street Journal that he has been taking higher doses of aspirin for "cardiac prevention" for ...